182 related articles for article (PubMed ID: 15544064)
1. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
Pharmazie; 2004 Oct; 59(10):812-3. PubMed ID: 15544064
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
AAPS PharmSciTech; 2004 Aug; 5(4):e65. PubMed ID: 15760062
[TBL] [Abstract][Full Text] [Related]
3. Development of liposomal amphotericin B dry powder inhaler formulation.
Shah SP; Misra A
Drug Deliv; 2004; 11(4):247-53. PubMed ID: 15371106
[TBL] [Abstract][Full Text] [Related]
4. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
5. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
6. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance.
Jones MD; Santo JG; Yakub B; Dennison M; Master H; Buckton G
Int J Pharm; 2010 May; 391(1-2):137-47. PubMed ID: 20211715
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols.
Alexander BD; Winkler TP; Shi S; Dodds Ashley ES; Hickey AJ
Pharm Dev Technol; 2011; 16(6):577-82. PubMed ID: 21699390
[TBL] [Abstract][Full Text] [Related]
8. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers.
Flament MP; Leterme P; Gayot A
Int J Pharm; 2004 May; 275(1-2):201-9. PubMed ID: 15081150
[TBL] [Abstract][Full Text] [Related]
9. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
You Y; Zhao M; Liu G; Tang X
J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
11. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
[TBL] [Abstract][Full Text] [Related]
12. Development of liposomal salbutamol sulfate dry powder inhaler formulation.
Huang WH; Yang ZJ; Wu H; Wong YF; Zhao ZZ; Liu L
Biol Pharm Bull; 2010; 33(3):512-7. PubMed ID: 20190418
[TBL] [Abstract][Full Text] [Related]
13. Influence of carrier surface fines on dry powder inhalation formulations.
Boshhiha AM; Urbanetz NA
Drug Dev Ind Pharm; 2009 Aug; 35(8):904-16. PubMed ID: 19466888
[TBL] [Abstract][Full Text] [Related]
14. Effect of interactive ternary mixtures on dispersion characteristics of ipratropium bromide in dry powder inhaler formulations.
Beilmann B; Kubiak R; Grab P; Häusler H; Langguth P
AAPS PharmSciTech; 2007 Apr; 8(2):Article 31. PubMed ID: 17622109
[TBL] [Abstract][Full Text] [Related]
15. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
16. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance.
Young PM; Chan HK; Chiou H; Edge S; Tee TH; Traini D
J Pharm Sci; 2007 May; 96(5):1331-41. PubMed ID: 17455362
[TBL] [Abstract][Full Text] [Related]
17. Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation.
Handoko A; Ian L; Peter SJ
Eur J Pharm Sci; 2009 Feb; 36(2-3):265-74. PubMed ID: 18996188
[TBL] [Abstract][Full Text] [Related]
18. Dispersibility of lactose fines as compared to API in dry powders for inhalation.
Thalberg K; Åslund S; Skogevall M; Andersson P
Int J Pharm; 2016 May; 504(1-2):27-38. PubMed ID: 26965200
[TBL] [Abstract][Full Text] [Related]
19. Entrainment of lactose inhalation powders: a study using laser diffraction.
Watling CP; Elliott JA; Cameron RE
Eur J Pharm Sci; 2010 Jul; 40(4):352-8. PubMed ID: 20417708
[TBL] [Abstract][Full Text] [Related]
20. In vitro deposition of the respirable fraction of dry powder inhalations determined by laser diffractometry and inertial impaction.
Marques HM; Schmidt PC
Pharmazie; 2002 Aug; 57(8):546-51. PubMed ID: 12227195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
